Lower survival rates for many cancer types correlate with increases or decreases in nuclear size/scaling in a tumor-type/tissue-specific manner. Postulating that nuclear size changes confer a fitness advantage on tumor cells, we screened for FDA/EMA-approved compounds that reverse tumor nuclear size changes in cell lines from three such tumor types: prostate adenocarcinoma, colonic adenocarcinoma, and small-cell squamous lung cancer. We found distinct, largely non-overlapping sets of compounds that either rectify or exacerbate nuclear size changes for each tumor type. Nuclear size phenotypes across cell lines clustered particular classes of compounds including serotonin uptake inhibitors, cyclo-oxygenase inhibitors, beta-adrenergic receptor agonists, monoamine oxidase inhibitors, and Na + /K + ATPase inhibitors. Nearly all compounds selected for further investigation inhibited cell migration and/or invasion, suggesting that targeting nuclear size control pathways in chemotherapy regimens could improve patient survival.
Introduction
Nuclear size changes have been used in cancer diagnosis since the 1860s 1 and are still used for diagnosis and prognostic grading of later stage, higher-grade tumors 2 . Characteristic nuclear size changes observed are independent of ploidy for at least a dozen cancer types, suggesting a primary dysfunction in regulation of size/scaling in the cell. However, it remains unclear whether nuclear size alterations contribute to increased metastasis, in part because the directionality and degree of size changes is tumor/tissue-type specific 3, 4 . For example, in small-cell squamous lung cancer and osteosarcoma smaller nuclear size correlates with increased metastasis 5, 6 while for breast, prostate, colon and several other cancer types increased nuclear size correlates with increased metastasis 7, 8, 9, 10 .
While absolute nuclear size changes are used in current diagnostics, in some tumor types the size change is associated with disruption of cell scaling 11 . In normal cells and tissues, the nuclear-to-cytoplasm (N/C) ratio, also called the karyoplasmic ratio, is maintained during the cell cycle 12, 13 , throughout which the nucleus increases several-fold in volume 14 . In contrast, the N/C ratio is altered in cancer cells by non-correlated changes in nuclear size and/or cell size. It has long been known that a general scaling mechanism for maintaining the N/C ratio is conserved from higher eukaryotes to yeast 15, 16 but the mechanistic basis for this scaling remains uncertain. A number of proteins have been implicated in regulating absolute nuclear size and N/C scaling. Nuclear size is influenced by nuclear envelope (NE) proteins, such as the lamins that form the nucleoskeleton 17 and the outer nuclear membrane nesprins that connect to the cytoskeleton 18 . The inner nuclear membrane protein LEM2 also regulates nuclear size by controlling membrane flow 19 , possibly through interactions with lamins, chromatin 20, 21 and protein kinases 22 . Recent genetic screens in yeast have implicated nucleocytoplasmic transport, LINC complexes, and RNA processing/splicing in nuclear size and N/C ratio control 23, 24, 25 .
As nuclear size and/or N/C ratio scaling is disrupted in cancer cells with increased metastatic potential, we reasoned that these changes might contribute an advantage to the tumor by facilitating metastasis. From a regulatory and structural perspective, the NE connects to both the genome and the cytoskeleton. Dysregulation of nuclear size could therefore yield metastatic advantages ranging from altered gene regulation, nuclear signalling and/or nucleo-cytoplasmic transport to mechanical effects enabling faster migration and/or easier invasion of cancer cells through epithelial barriers. Indeed, disruption of laminA reduces cell migration 26 . Moreover, mechanical forces that would be expected to be altered by nuclear size changes are important for the progress of metastasis 27 and cellular traction stresses are linked to metastatic potential 28 . For these reasons, we speculated that restoring nuclear size to a more normal range might reduce metastatic potential.
As each tumor/tissue type has different characteristic size/scaling changes, and because many parameters likely affect nuclear size, it is difficult to correlate cancer genome sequence information with alterations in nuclear size control. Here, we used a chemicalgenetic approach to systematically probe the pathways that affect nuclear size in cancer cells.
We screened for FDA/EMA-approved compounds that rectify nuclear size in three cancer cell lines derived from different tissues: two in which nuclear size increases correlate with worse grade (prostate, colon adenocarcinoma) and one in which nuclear size decrease correlates with worse grade (lung). The majority of compounds identified had tumor/tissue/cell linespecific effects on nuclear size or scaling, typically only affecting one of the three cancer cell lines. Clustering compounds according to their therapeutic classes/mechanism of action identified many compound classes with characteristic nuclear size phenotypic signatures across cell lines and conditions. Among these, some altered the absolute nuclear size but not N/C ratio or vice-versa, suggesting different modes of action. Detailed investigation of five compounds revealed cell line-specific effects on cell invasion, consistent with nuclear size changes observed. These results suggest that pharmacological restoration of nuclear size control represents a new strategy to combat metastatic cancer.
Results
Nuclear size/scaling chemical screen. We screened for compounds that alter nuclear size and/or N/C ratio in three tumor types using a microscopy-based approach (Fig. 1 ). PC3 and HCT116 cells respectively represented late-stage prostate cancer and colonic adenocarcinoma where nuclear size increases compared to the healthy tissues reflect worse cancer grades. H1299 cells represented small-cell squamous lung carcinoma where decreased nuclear size correlates with a worse grade. Cells plated onto 96-well optical plates were treated for 6 h or 36 h with the Prestwick chemical library of 1,120 previously approved drugs (PAD, 2015 version), all at a concentration of 10 µM. We chose the 6 h time-point to reveal compounds that did not require post-mitotic NE re-assembly to elicit size changes and the 36 h timepoint to identify compounds with low toxicity. To align with standard cancer diagnostic procedures, we used nuclear/cell area from imaging (focal) cross sections as our core size metric, as opposed to 3D reconstruction of nuclear/cell volume. Nuclear area was monitored with stably expressed H2B-mRFP and total cell area from CellMask DeepRed cytosol staining (Fig. 1a ). 350-1,000 cells/condition were imaged using a Perkin-Elmer OPERA TM confocal microscope for each screen. Two full replicate screens were undertaken for each cell line and treatment duration, based on reproducibility in a pilot screen using three replicates (Methods; Supplementary Figure S1 ; Supplementary Table S1 ).
Two complementary quantification strategies, one average-based and the other outlier-based, were used to analyse effects of compounds on both the absolute nuclear size and the N/C ratio (i.e., relative nuclear size). Hence, we performed four separate analyses of the dataset. Average-based analyses are traditionally used by cytologists to grade tumors 29, 30 .
To implement this approach, the average values of the size metrics were determined across all imaged cells for each compound well and in-plate DMSO-treated controls. However, shifting the average metric values up or down does not obligatorily reflect loss of size regulation, but could reflect a change in the cell-regulated value to which the metric is set.
Thus, to detect compounds that specifically disrupt nuclear size control by increasing the metric variance across a cell population, we also analysed the same data using an outlier-based approach. We computed for each well the fractions of cells with abnormally large or small metric value (i.e., outlier cells). The outlier metric value refers to values beyond the outlier thresholds defined using standard procedures with respect to the distribution of metric values for all in-plate DMSO control wells (see Fig. 1B and Methods). For the average-based and outlier-based methods, respectively, the average metric values and the fractions of outlier cells from all wells were analysed statistically to identify hit compounds that perturb the metric beyond the typical metric variability across the library. This approach should reduce nonspecific compound effects on nuclear size (see Methods). Hit compounds were confirmed using direct comparison with in-plate DMSO controls in Wilcoxon rank statistical tests.
Strikingly, we observed little overlap in the sets of compounds affecting absolute nuclear size between the different cell lines using average-based analysis ( Fig. 2a ; Table 1 ; Supplementary Table S2 ). The combined short (6 h) and long (36 h) time-points yielded a total of 112 compound hits that altered mean nuclear size in PC3 cells (32 increase, 80 decrease), 105 hits in HCT116 cells (35 increase, 70 decrease) and 111 hits in H1299 cells (70 increase, 41 decrease). Compounds with the strongest functional effects are listed in Table 1 . Different compounds reversed cancer-associated nuclear size changes either in a cell line-specific or non-specific manner ( Table 1 , Supplementary Figure S2 ). Cell types in which worse grade correlated with increased nuclear size (PC3, HCT116) had more active compounds at the long treatment time while the cell type in which smaller nuclear size correlated with worse grade (H1299) yielded more active compounds at the short treatment time ( Fig. 2b ; Table 1 ; Supplementary Table S2 ). It is possible that long term effects on nuclear size may indicate a requirement for restructuring the NE in mitosis, while selective short-term effects may indicate homeostatic adaptation to perturbation.
There was a strong overlap between compound sets identified using average-based versus outlier-based analyses for absolute nuclear size although the outlier-based method tended to identify more hits (Supplementary Figure S2a , Table 1, compare Supplementary   Tables S2, S4 ). The convergence of two fundamentally different analysis methods underscores the robustness of our data. At the same time, differences between the two analyses might be biologically relevant. In particular, average-based only hits might alter the nuclear size set point but not homeostatic control whereas outlier-based only hits might perturb homeostasis but not the nuclear size set point.
We carried out analogous average-and outlier-based analyses of the N/C ratio, which normalizes nuclear size changes relative to overall cell size. Both analyses identified cancertype specific compound sets, with many compounds the same as those identified by the absolute nuclear size analyses ( Fig. 2c-d ; Table 1 ; Supplementary Tables S3, S5 ). However, N/C ratio analyses identified many additional compounds. Combining short and long timepoints for the average analysis yielded a total of 237 hits for PC cells (149 increase, 188 decrease), 287 hits in HCT116 cells (173 increase, 114 decrease) and 246 hits in H1299 cells (118 increase, 128 decrease). That more than twice as many compounds were identified by the N/C ratio analysis than absolute nuclear size indicates that many compounds can also affect cell size.
In the following sections, unless otherwise specified, we used the absolute nuclear size metric and the average analysis methodology. This metric/methodology association gave the most reproducible results in our triplicate pilot screen (Supplementary Figure S1 ; Supplementary Table S1 ). We used comparison of absolute and relative nuclear size metrics across time-points to provide mechanistic information on whether the compounds act in a cell size-dependent or -independent fashion. We used comparison of average and outlier analyses to discover compounds that alter nuclear size setpoint per se as opposed to General versus cell line-specific compound classes. All compounds were sorted according to pharmacological class/mechanism-of-action and clustered according to increased ( Fig. 3 ) and decreased ( Fig. 4 ) nuclear size phenotypes. Strikingly, certain compound classes showed phenotypic clustering across cell lines. DNA intercalating agents increased absolute nuclear size (but less so the N/C ratio) in all three cell lines (Supplementary Figure S3a) , with strongest effect at the 36 h timepoint. Microtubule polymerisation inhibitors similarly tended to increase the fraction of cells with abnormally large nuclei across all cell lines, also with enrichment at the longer timepoint (Supplementary Figure   S3b ). However, microtubule poisons also increased the fraction of cells with abnormally small nuclei, such that the overall effects on average nuclear size were subtle. In particular, microtubule poisons increased the fraction of PC3 cells with abnormally large N/C ratios at 6 h without affecting the proportion of cells with large nuclear size ( Supplementary Figure S3c , compare bottom and top heat maps). In contrast, by 36 h the initial increase in N/C ratio disappeared while nuclear size was now strongly affected in both directions. Microtubule poisons such as fenbendazole, colchicine, nocodazole, paclitaxel, albendazole, and podophyllotoxin may initially increase nuclear size, but the cell subsequently adjusts its cytoplasm to compensate. These results illustrate that multiparametric analyses can reveal size and scaling defects that would be missed by monitoring only a single parameter. As both DNA intercalating agents and microtubule polymerisation inhibitors are mainstays of chemotherapy regimens, these findings also exemplify the utility of the nuclear size screens in identifying general anti-cancer compounds. Indeed, our screens recovered most known antineoplastic compounds present in the Prestwick library, with variable effects on nuclear size (Supplementary Figure S3d ). However, as such chemotherapeutic agents are generally toxic we focused on compounds with cell-type specific effects that may circumvent this drawback.
As nuclear size changes can occur in both directions, we refer to any compound that reversed a cancer-associated nuclear size phenotype as a nuclear size rectifier (NSR), whether it acts to make a large nucleus smaller or a small nucleus larger. Several compound classes were NSRs in only one or two of the three cancer cell lines ( Fig. 5 ). Beta-adrenergic receptor agonists (BAAs, Fig. 5a ) such as salbutamol, fenoterol, clenbuterol, isoetharine mesylate, and isoproterenol, but not antagonists such as propafenone, levobunolol, and betaxolol (Supplementary Figure S4a ), reduced the nuclear size of HCT116 cells and increased the nuclear size of H1299 cells, i.e., towards a more normal size in both cases.
BAAs affected absolute nuclear size but not the N/C ratio in H1299 cells while affecting N/C ratios and not absolute nuclear size in HCT116 cells (compare Fig. 5a with Supplementary Figure S4a ). This example illustrates that the same compound class can elicit distinct nuclear size changes in different cell lines/cancer types. In contrast, Na+/K+ ATPase inhibitors, such as digitoxigenin and lanatoside, selectively increased nuclear size only in H1299 cells ( Fig.   5a ) and thus may exhibit selectivity towards lung cancer. Similarly, glucocorticoids increased absolute nuclear size and to a lesser extent the N/C ratio specifically in HCT116 cells (Supplementary Figure S4b) . The widespread use of glucocorticoids in colon cancer therapy 31 may thus engender unintended adverse characteristics.
We also identified NSR compounds that decreased nuclear size in PC3 prostate cancer cells including cyclo-oxygenase inhibitors and the 5-HT reuptake inhibitor class of antidepressants ( Fig. 5b ). For the latter compounds (e.g., sertraline, paroxetine), the decrease in absolute nuclear size was sometimes accompanied by an increased N/C ratio after the early but not late time point, again consistent with potential homeostatic control mechanisms that act on the N/C ratio. Similar behaviour was observed for GABA receptor ligands/agonists on HCT116 colon cancer cells, whereby the drugs decreased absolute nuclear size but with an even greater effect on cell size, such that the N/C ratio was increased (Supplementary Figure   S4b ). The terpenoid natural product cantharidin, which has anti-viral and anti-proliferative effects, was a potential PC3 NSR that strongly decreased absolute nuclear size in PC3 cells while increasing the N/C ratio, both after 6 h and 36 h treatment ( Figure 5c ). In addition to the above illustrative examples, our nuclear size screens identified ~50 other NSR compounds for the different cancer types ( Table 1 ; Supplementary Figure S5 ). Thus, just as nuclear size changes are characteristic for each tumor type, many compounds that normalize these nuclear size defects are often specific to each cell type and exert effects on relative and/or absolute nuclear size metrics.
NSRs have heterogeneous effects on cell viability. It is unclear whether nuclear size
changes directly drive aggressive metastatic behaviour or if the alterations in nuclear size are a by-product of other aspects of tumor progression. To address this question, we selected 5 NSR compounds to test for properties relating to tumor growth and spread. The compounds selected covered a range of target specificities and directions of size changes (Table 2) .
Oxyphenbutazone, a non-steroid anti-inflammatory drug, which also depolymerises microtubules, decreased nuclear size in all three cell lines and at both 6 and 36 h time points, but specifically decreased the N/C ratio only in PC3 cells. Parbendazole, an anti-helminthic, increased relative nuclear size in all three cell lines but only at the 36 h time point.
Digitoxigenin, a steroid lactone used to strengthen heartbeat that also has anti-cancer activity, dramatically increased nuclear size in H1299 cells but less so in HCT116 cells.
Piperlongumine, an alkaloid natural product with claimed anti-cancer properties 32 , increased the N/C ratio in PC3 cells at 6h but decreased absolute nuclear size after 36 h and increased nuclear size in HCT116 and H1299 cells at 36 h. Finally, paroxetine, an anti-depressant that blocks serotonin uptake, was the most specific of the compounds tested as it caused a nuclear size decrease only in PC3 cells.
All five compounds reduced the viability and proliferative capacity of each cancer cell lines to different degrees, as assessed using an assay to quantify metabolically active cells in the population (Fig. 6a ). Briefly, ~5,000 cells were plated into each well of 96-well plates, drugs were added in serial dilutions and incubated for 36 h, then resazurine was added, which only reduces to fluorescent resorufine in metabolically active cells. Oxyphenbutazone decreased nuclear size in all three cancer lines and decreased cell viability similarly for PC3 cells and HCT116 cells, i.e., the two lines that exhibit a large nuclear size. In H1299 cells, which have a small nuclear size, viability decreased even more rapidly. In contrast, parbendazole, which increased nuclear size in all three lines had its strongest effect on viability of H1299 cells, i.e., in a context where it reversed the small nuclear size associated with tumor aggressiveness.
To test if the concentrations that affected nuclear size might suffice to initiate apoptosis, we also performed Annexin V staining. As compounds that induce necrosis and consequent inflammation would have negative side effects if used therapeutically, we also stained cells with propidium iodide to distinguish necrotic cells. This co-staining protocol was applied to PC3 cells and resulted in 4 different cell populations: healthy cells with no staining, early-stage apoptotic cells positive only for Annexin V, late stage apoptotic cells positive for Annexin V and propidium iodide, and necrotic cells positive only for propidium iodide. Note that the first three populations are expected to contribute to resorufine fluorescence. The percentage of cells in each population was determined by fluorescence activated cell sorting (FACS). PC3 cells were incubated with drugs, refreshing the medium with drug every 24 h, and gating set to detect only singlets and intact cells ( Fig. 6b ). Plotting the percentage of cells in each category ( Fig. 6c ) revealed that digitoxigenin strongly triggered apoptosis with roughly 10% of cells in early apoptosis and ~70% in late apoptosis. Parbendazole, oxyphenbutazone, and piperlongumine all yielded ~40% cells in apoptosis, though with different percentages in early and late stages. Paroxetine, the only compound with a PC3-specific effect on nuclear size, induced neither apoptosis nor necrosis. From these results we concluded that there is no obvious correlation between effects on nuclear size and cell viability.
NSRs inhibit cell migration and invasion.
As nuclear size changes correlate with higher cancer grade and increased metastasis, we reasoned that drug-induced nuclear size corrections might affect cell migration or invasion. Size and scaling changes likely affect nucleoskeleton-cytoskeleton connections that in turn could affect cell migration, as previously indicated by slower cell migration with both knockout and overexpression of laminA, respectively in 2D and 3D assays 26, 27, 28, 33 . We tested a subset of the compounds identified in our screens for effects on cell migration in a scratch-wound healing assay ( Fig. 7a -c). To be certain wound closure reflected cell migration and not cell division, cells were starved with 1% FBS containing medium 16 h before the scratch. Cells were treated with serial dilutions of compounds in four replicates immediately following the scratch and were recorded every 3 h for 48 h. Analysis of wound closure times against controls revealed that in PC3 cells oxyphenbutazone reduced migration in a dose-dependent manner at concentrations of 100 nM and higher. Parabendazole similarly inhibited migration but at higher concentrations of 1 µM or greater ( Fig. 7a,b ). Paroxetine did not have a quantifiable effect on PC3 cell migration in this assay system.
Considering that many compounds only affected nuclear size in certain cancer lines, we tested the other two compounds in both PC3 cells and H1299 cells. Piperlongumine also inhibited cell migration at 1 µM and higher in PC3 cells but had no effect on H1299 cells.
Conversely, digitoxigenin inhibited cell migration of H1299 cells at 100 nM and higher, but exhibited no effect on PC3 cells (Fig. 7c ). Unlike cell viability assays, the results of these migration assays were concordant with compound effects on nuclear size, i.e., compounds that rectified cancer-associated nuclear size changes (NSRs) also had anti-migration properties.
The effects in the wound healing assays could reflect reduced mobility or loss of directionality or both. To test for loss of cytoskeletal polarization, cells were stained for gamma tubulin to determine centriole orientation. After a scratch wound normal cells orient with the centriole facing the wound in order to direct inward migration and wound closure.
Piperlongumine, digitoxigenin and paroxetine were tested in PC3 cells and each was found to cause a defect in centriole orientation in 65-85% of cells scored (Fig. 7d ).
We considered the possibility that compound effects on nuclear size might reverse an advantage of the tumor cells to migrate through tight junctions. A weaker nucleoskeleton can enable squeezing through constrictions despite a larger nuclear size while a stiffer nucleoskeleton could enable smaller nuclei to move faster through constrictions 33, 34 . We tested the ability of the PC3 cells to migrate through 5x15 µm 2 and 5x2 µm 2 constrictions in the presence or absence of compounds. The small pore constrictions require substantial nuclear deformation, while the larger pores exceed the size of the nucleus and thus partly serve as controls for migratory ability in a 3D environment (Fig. 7e ). The mean migration speed was slightly slower for piperlongumine-treated cells through the 5x15 µm 2 constrictions (79 min) versus DMSO solvent control (91 min). Similarly, digitoxigenin-treated cells exhibited a slightly slower mean migration speed than controls (73 min versus 82 min) through the smaller 5x2 µm 2 constrictions. However, in both cases the difference did not reach statistical significance. As cells do not need nucleo-cytoskeletal connections to squeeze through the constrictions and the centriole was not oriented towards the scratch in the wound healing assays, the lack of statistical significance suggests that the slower migration in the scratch wound assays may arise from defects in 2D cell polarization. As cells can use different migration modes in 2D wound healing assays versus 3D chamber migration assays 33, 34, 35 , these results are consistent with the effects of the compounds in wound healing assays but suggest that the effects have more to do with reduced mobility and directionality than with a change in mechanical stiffness.
A transwell migration assay was performed ( Fig. 7f ) to investigate compound effects on PC3 invasion. Cells were seeded on the inside Boyden chamber in absence of FBS on a 3 µm pore membrane coated with ECM proteins and submerged on the outside Boyden chamber in conditioned media as chemoattractant. Cells were allowed to migrate through the membrane for 24 h in the presence of compounds at the 10µM concentration used in the size screen, and the relative number of cells migrating was quantified with a colorimetric assay.
Cells treated with piperlongumine and parbendazole had ~50% fewer cells migrate through the membrane compared to DMSO-treated controls, where oxyphenbutazone and digitoxigenin reduced the invasion capability by 15% and 30% respectively. Thus, NSR compounds reduced both cell migration and invasion in tissue culture assays.
Discussion
We postulated that nuclear size changes that correlate with increased metastasis might contribute directly to metastasis through changes in cellular mechanics and/or migration.
Screening for compounds that alter nuclear size in 3 distinct cancer types revealed different sets of compounds affecting each and most of the compounds tested inhibited cell migration.
Many of the FDA/EMA-approved compounds that we show have cell line-specific NSR activity in reversing the direction of cancer size changes have not been previously tested for cancer therapies for these tumor types. Our data indicated that DNA intercalants and microtubule 24 ), nuclear/cell scaling and nuclear size regulation have tissue-specific components. It is tempting to speculate that, as higher organisms developed more specialised tissues, the unique connections of the NE for different tissue functions became entwined with scaling regulation. For example, an ovary needs a different scaling regulation to support nutrient storage while colonic epithelia have polarized cytoskeleton connections to the nucleus. These mechanisms could be hijacked in tumorigenesis to achieve observed tissue-specific nuclear size changes. Such differences in mechanism and function could impact on whether or not the size change confers an advantage to the cancer in a particular cell type.
Many compounds not only differed in their tissue-specific effects on nuclear size but also in their effects on absolute versus relative nuclear size. We speculate that disruption of nuclear scaling (i.e., N/C ratio) might be a fundamental aspect of metastasis such that reversing the scaling defect might yield a less aggressive tumor. However, even if the scaling change is not fundamental to tumorigenesis, restoring normal nuclear size might prevent metastatic spread if the initial size change altered nuclear plasticity to facilitate squeezing through constrictions ( Fig. 8a ) or increased tumor cell motility (Fig. 8b) .
The nucleus is the largest and sturdiest organelle and thus the greatest impediment to cell migration through tight constrictions, such as when a metastatic cell migrates into other tissues. Making the nucleus smaller could promote metastasis by facilitating cell squeezing through cell-cell junctions while a larger nucleus -without an increase in ploidy so that the DNA is less compact-may more readily deform to squeeze through cell-cell junctions ( Digitoxigenin is an effective chemotherapeutic against metastatic uveal melanoma 39, 40 and its derivative, amantadig, is effective in inhibiting hormone-refractory prostate cancer cells 41 , but the mechanism by which it acts is not clear and may even differ in different cancer types.
Piperlongumine has been used to treat breast cancer in xenograft models, causing a reduction of tumor volume and metastasis 42, 43 and this activity is thought to function through ROS-mediated apoptosis 32, 43, 44, 45 . Piperlongumine also has also been reported to inhibit glycolysis and FOXO3A, and to have senolytic and antimicrobial activity 46, 47, 48, 49 . How these mechanisms relate to piperlongumine effects on nuclear size remain to be determined.
The other compounds we tested for migration effects have not been used to our knowledge as anti-cancer agents, nor can their known targets readily explain their effects on nuclear size regulation. Paroxetine is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class and is used to treat depressive and obsessive-compulsive disorders.
Paroxetine interacts with cytochrome P450 complex enzymes 50 and promotes mitochondrialinduced apoptosis in astrocytes 51 . Parbendazole is a benzimidazole derivative showing broadspectrum anthelminthic activity and is also a potent microtubule assembly inhibitor 52, 53 .
Parbendazole induced apoptosis in nearly 40% of PC3 cells and inhibited cell migration by nearly 75% in wound healing assays and by 50% in invasion assays. Thus, even though this compound is from a group of drugs with anti-helminthic activity, it may hold promise as an anti-cancer therapeutic.
Other anti-helminthics affected nuclear size in our study as well as several other compound classes not further investigated. Thus, several compound classes not previously used in cancer treatments might be repurposed to treat particular cancer types. For some compound classes this has already been achieved. For example, BAAs were NSRs for colonic adenocarcinoma and small cell lung cancer cells. Interestingly, BAAs suppress the epithelial to mesenchymal transition of bronchial epithelial cells and have been used to treat lung cancer 54, 55 . BAAs also inhibit cancer pathways for triple-negative breast cancer and gliomas 56, 57 , and the agonist salbutamol reduces migration and invasion of breast cancer cells 58 . Tissuespecific context for BAAs may be critically important, however; for example, beta-adrenergic receptor signaling promotes angiogenesis of gastric tumors 59 . Serotonin reuptake inhibitors are another NSR class that has recently been repurposed to treat glioblastoma 60 and shown promise in model systems against hepatocellular carcinoma 61, 62 .
This study provides proof-of-principle to the hypothesis that targeting tissue/cancer type nuclear size changes can affect cell migration with the potential to reduce metastasis.
Accordingly, similar screens should be engaged for other cancer/tissue types and the compounds identified tested in animal models. The new compounds and compound classes identified in this study will likely enhance anti-cancer therapies by increasing tissue-specificity, reducing toxicity, and directly targeting metastasis. Due to their tissue-specificity, combining them with current chemotherapy regimens should allow for reduction of some of the compounds that target all cell types and thus yield systemic toxicity. Most critically, the tendency of compounds affecting nuclear size to also reduce cell migration and invasion suggests that their inclusion in treatment regimens could reduce the metastasis that is usually the primary cause of mortality and thus improve long-term survival.
Methods
Cell lines. PC3, HCT116, and H1299 cells were stably transfected to express H2B-mRFP in the pEGFP-N2 clontech vector and maintained under G418 selection (500_µg/mL) for general culture. Selection was removed for 1 passage prior to plating for experiments to avoid drug interference effects. including cell and nuclear sizes, and average signal intensities in the two compartments were saved as text files and loaded in MATLAB for statistical analysis (Fig. 1, see below) . Identical detection and filtering parameters were used in Acapella ® to identify cells and nuclei under all conditions to homogenize data analysis and prevent post-acquisition processing biases. For conditions that yielded higher cell densities at the time of imaging, the above filtering step was sometimes insufficient to remove clusters of cells so cell size outliers were eliminated from all datasets. For each condition separately, the entire cell size distribution was analysed and we extracted the 25%, 50% and 75% size quartiles (Q1, Q2 and Q3 respectively). Following standard outlier removal procedures, we filtered out detection areas with a size larger than the outlier threshold Q2+6*(Q3-Q2) (i.e., likely cell clusters), and the detections smaller than Q2-6*(Q2-Q1) (i.e., imaging artefacts or cell debris). All DMSO control wells for each plate were processed together in this step.
For each detected cell that passed through data filtering steps, we computed two metrics: the absolute nuclear size N, and the relative nuclear size, or N/C ratio, defined as the ratio of the absolute nuclear size to the absolute cell size (i.e., the area of the CellMask DeepRed signal focal cross-section in pixels).
ii) Statistical analysis of distributions -average-based and outlier-based strategies:
Compounds that altered absolute or relative (N/C) nuclear size metrics were identified using two complementary strategies for each metric.
Average-based strategy: first, for each plate/replicate, the average value of the metric across all detected cells was determined for each compound-treated well and for all in-plate DMSO control wells. Hits were selected as compounds with an average metric value that stands out from the distribution of average metric values across the library. Specifically, we computed the 25%, 50% and 75% percentiles of the distribution of well-averaged metric values across the library for each cell line/replicate separately (respectively denoted Q1, Q2 and Q3). Then low and high outlier thresholds were computed following standard procedures, respectively as
. In standard procedures, the parameter s is generally chosen as ‫ݏ‬ ൌ 6
for hard hit selection and ‫ݏ‬ ൌ 3
for soft hit selection. We used the former for the absolute nuclear size metric and the latter for the N/C ratio metric. N/C ratio cell-to-cell variability exceeded absolute nuclear size cell-to-cell variability, likely because the N/C ratio originates from 2 different measurements (nuclear size and cell size), both of which are associated with measurement uncertainty and biological variability. Hence, in order not to reduce the hit discovery potential of the N/C metric, we used slightly less stringent criteria for hit selection with this metric. This may explain, in part, the increased sensitivity of the N/C ratio relative to nuclear size in identifying active compounds.
These pairs of thresholds are represented as dashed red lines on Supplementary Figure S1B . Such compounds were designated as hits for the corresponding metric and the average-based analysis strategy.
Outlier-based strategy: For each plate, we computed the 25%, 50% and 75% percentiles characterizing the distribution of metric values across the population of individual DMSOtreated control cells only (i.e., 16 wells per plate). We used these percentiles (Q1, Q2, Q3) to compute low and high (soft) outlier thresholds as defined above
. Cells with values below the low threshold were designated as having an abnormally small metric; likewise, the high threshold represents the metric value above which a cell was designated as having an abnormally large metric. We next used these thresholds to compute, for all DMSO control and compound wells, the fractions of cells showing abnormally small and large metric values (relative to the in-plate DMSO distribution), i.e. such that
respectively (Fig. 1B, central plot, red-shaded areas). These fractions were typically 0-10% for
DMSO controls and cells treated with compounds showing no specific effect on nuclear size.
These numbers reflected the biological and measurement-related cell-to-cell variabilities in our dataset. However, these fractions could reach 20-30% of the cells or even more for the strongest compounds (e.g. oxyphenbutazone, Fig. 1B right plot) . Thus, compounds that deregulate the metric beyond the expected variability in our entire dataset are compounds that enrich one or both of those fractions of outlier cells above this typical level defined by DMSO controls and other compounds. To detect these compounds, we computed the entire distributions of each of these fractions of outlier cells separately across the entire compound collection, computed the 25%, 50% and 75% percentiles that characterize the distributions of those fractions of outlier cells with abnormally small/large metric value across the library (Q1 small/large , Q2 small/large and Q3 small/large ), and defined hit detection thresholds as
. We note that the qualitatively different nature of the analyses and the corresponding thresholds used could explain differences in hit counts between average and outlier analyses. Pilot screen. To estimate the accuracy of these analysis strategies and assess screen reproducibility, we ran a pilot screen on PC3 cells at the 6 h time point in triplicate (Table S1 and Supplementary Figure S1 ). For each hit, obtained using absolute or relative (N/C ratio) nuclear size metrics (rows 1-2 and 3-4 respectively), the distributions of mean metric values Table S1 . As a result, ~85-100% of the hits that replicated twice and three times had low p-values irrespective of the metric/analysis strategy. A large fraction of hits that scored only once out of three replicates still showed statistical significance upon direct comparison with DMSO controls, in particular for the nuclear size metric analysed with the average-based strategy. This reflected scores slightly below hit detection thresholds, as
can be viewed on scatter plots showing the raw data across replicates for three plates (240 compounds, Supplementary Figure S1B ). Of note, some compounds that never scored above detection thresholds nevertheless did show statistically significant altered nuclear size.
However, these compounds were not analysed further. The rather low false discovery rate <20% for hits determined using average-based analysis of absolute nuclear size prompted us to downsample larger screens to duplicate screens, and to use this metric and analysis method as the default hit discovery methodology. Relative nuclear size metric (as quantified by the N/C ratio) and outlier-based analysis were used as indicated in the main text to provide additional contrasts to emphasize the phenotypic specificity of particular compound classes. Microfluidic device migration assay. PC3 cells were seeded into a previously described microfluidic device for studying nuclear transit during confined migration 63 . The device consists of migration channels with a fixed height of 5 µm and constrictions of 1 to 2 µm or 15 µm in width. Devices were assembled as previously described and coated with a solution of 5 µg/mL of fibronectin 24 h prior to experiments 64 . 30,000 cells were seeded into each device 6 h prior to imaging and were treated with either piperlonguine, digitoxigenin, or DMSO control.
Imaging was performed on a Zeiss LSM700 laser scanning confocal microscope with a 20x air objective. Cells and devices were imaged at 10 min intervals in a temperature controlled stage (37°C) for 14 h. The time required for cells to migrate through an individual constriction was quantified using a previously described MATLAB script for measuring nuclear transit through these microfluidic devices 65 . 
Data availability
Data generated or analysed during the current study are included in the published manuscript and its supplementary information files.
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